The title should be "a missed hope" because I have missed this trial, it started a couple of months ago! But it's still recruiting!
INV-9956 is an orally available, highly selective CYP11A1 inhibitor designed to reduce androgen production, a key driver of prostate cancer growth. Preclinical studies show that INV-9956 effectively suppresses tumor proliferation, particularly in drug-resistant castration-resistant prostate cancer (CRPC) with AR mutations like AR L702H.
In vivo models demonstrated superior tumor inhibition and a favorable safety profile compared to existing options. Currently in Phase 1 clinical trials, INV-9956 is being tested for safety, pharmacokinetics, and antitumor activity in patients with advanced mCRPC. These findings highlight its potential as a breakthrough treatment for resistant prostate cancers.
